Subscribe
shutterstock_1843221310_maxshot_pl
MAXSHOT.PL / Shutterstock.com
1 June 2022Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Foley Hoag adds partner in Boston
22 August 2023   Biologics patent attorney aims to strengthen the firm’s global patent networks.
Big Pharma
GSK signs licence deals with three generics firms to make HIV preventative for low income countries
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Big Pharma
Foley Hoag adds partner in Boston
22 August 2023   Biologics patent attorney aims to strengthen the firm’s global patent networks.
Big Pharma
GSK signs licence deals with three generics firms to make HIV preventative for low income countries
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More on this story

Big Pharma
Foley Hoag adds partner in Boston
22 August 2023   Biologics patent attorney aims to strengthen the firm’s global patent networks.
Big Pharma
GSK signs licence deals with three generics firms to make HIV preventative for low income countries
30 March 2023   The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?